Metoprolol succinate versus metoprolol tartrate
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol Succinate vs. Metoprolol Tartrate: A Comparative Analysis
Introduction to Metoprolol Formulations
Metoprolol, a beta-blocker commonly used to treat cardiovascular conditions, is available in two primary formulations: metoprolol succinate (MS) and metoprolol tartrate (MT). Both formulations are used to manage conditions such as heart failure, hypertension, and angina, but they differ in their pharmacokinetic properties and clinical applications.
Hemodynamic Effects in Heart Failure
Studies comparing the hemodynamic effects of MT and MS in patients with congestive heart failure (CHF) have shown that both formulations produce similar long-term benefits in terms of functional, exercise, and hemodynamic parameters. However, during chronic therapy, both MT and MS exhibit parallel adverse hemodynamic effects, such as decreased cardiac index and stroke volume index, and increased systemic vascular resistance . This suggests that while both formulations are effective, they also share similar drawbacks in terms of hemodynamic stability.
Mortality and Hospitalization in Heart Failure
A meta-analysis comparing carvedilol and metoprolol (both tartrate and succinate) in patients with heart failure with reduced ejection fraction (HFrEF) found no significant difference in all-cause mortality or hospitalizations between carvedilol and metoprolol succinate. However, metoprolol tartrate was associated with higher mortality compared to carvedilol . This indicates that metoprolol succinate may be preferable over metoprolol tartrate in terms of long-term survival benefits in heart failure patients.
Cardiac Function and Heart Rate
In patients with chronic congestive heart failure, metoprolol succinate sustained-release tablets were found to decrease the average heart rate more effectively than metoprolol tartrate tablets, although both formulations had similar effects on cardiac and renal function . Additionally, in acute myocardial infarction patients, both formulations showed a significant reduction in heart rate over 72 hours, with no significant difference in the degree and trend of heart rate reduction between the two groups .
Pharmacokinetic and Pharmacodynamic Properties
The pharmacokinetic and pharmacodynamic profiles of metoprolol succinate and metoprolol tartrate differ significantly. Metoprolol succinate, with its controlled-release formulation, provides a more stable plasma concentration and a consistent beta1-blocking effect throughout the day, reducing the peaks and troughs associated with metoprolol tartrate . This results in a more constant therapeutic effect, which can be particularly beneficial in managing conditions requiring steady beta-blockade.
Clinical Efficacy in Hypertension and Angina
In the treatment of mild hypertension, both metoprolol succinate and metoprolol tartrate were effective in lowering blood pressure, but metoprolol succinate was more effective in reducing the morning blood pressure peak and increasing heart rate variability . For vasospastic angina, metoprolol succinate was superior in reducing the incidence of clinically significant angina attacks compared to metoprolol tartrate, although both formulations had similar rates of adverse cardiovascular events .
Conclusion
Both metoprolol succinate and metoprolol tartrate are effective in managing various cardiovascular conditions, but they have distinct pharmacokinetic and pharmacodynamic profiles that may influence their clinical use. Metoprolol succinate offers advantages in terms of stable plasma concentrations and consistent therapeutic effects, making it preferable in certain clinical scenarios such as heart failure and hypertension. However, metoprolol tartrate remains a viable option, particularly when cost considerations are paramount. Clinicians should consider these differences when choosing the appropriate formulation for their patients.
Sources and full results
Most relevant research papers on this topic